natgillin/translations-raw huggingface dataset:
Emballage Blister (PVC/ PE/ PVDC/ alu) Blister (PVC/ PE/ PVDC/ alu) Blister (PVC/ PE/ PVDC/ alu) Blister (PVC/ PE/ PVDC/ alu) Blister (PVC/ PE/ PVDC/ alu) Blister (PVC/ PE/ PVDC/ alu) Blister (PVC/ PE/ PVDC/ alu) Blister (PVC/ PE/ PVDC/ alu) Blister (PVC/ PE/ PVDC/ alu) Blister (PVC/ PE/ PVDC/ alu) Blister (PVC/ PE/ PVDC/ alu) Blister (PVC/ PE/ PVDC/ alu) Blister (PVC/ PE/ PVDC/ alu) Blister (PVC/ PE/ PVDC/ alu)
Packaging Blister (PVC/ PE/ PVDC/ alu) Blister (PVC/ PE/ PVDC/ alu) Blister (PVC/ PE/ PVDC/ alu) Blister (PVC/ PE/ PVDC/ alu) Blister (PVC/ PE/ PVDC/ alu) Blister (PVC/ PE/ PVDC/ alu) Blister (PVC/ PE/ PVDC/ alu) Blister (PVC/ PE/ PVDC/ alu) Blister (PVC/ PE/ PVDC/ alu) Blister (PVC/ PE/ PVDC/ alu) Blister (PVC/ PE/ PVDC/ alu) Blister (PVC/ PE/ PVDC/ alu) Blister (PVC/ PE/ PVDC/ alu) Blister (PVC/ PE/ PVDC/ alu)
Pakningsstørrelse 14 tabletter 28 tabletter 56 tabletter 112 tabletter 168 tabletter 196 tabletter 50x1 tabletter 14 tabletter 28 tabletter 56 tabletter 112 tabletter 168 tabletter 196 tabletter 50x1 tabletter
Package size 14 tablets 28 tablets 56 tablets 112 tablets 168 tablets 196 tablets 50x1 tablets 14 tablets 28 tablets 56 tablets 112 tablets 168 tablets 196 tablets 50x1 tablets
Velmetia 50 mg/ 850 mg filmovertrukne tabletter.
Velmetia 50 mg/ 850 mg film-coated tablets
Kapselformet, lyserød filmovertrukken tablet med "515" præget på den ene side.
Capsule-shaped, pink film-coated tablet with “ 515 ” debossed on one side.
Velmetia er også indiceret som supplement til diæt og motion i kombination med et sulfonylurinstof (dvs. tripel kombinationsbehandling) hos patienter, der ikke er tilstrækkeligt kontrolleret på den maksimalt tolererede dosis metformin og sulfonylurinstof.
Velmetia is also indicated in combination with a sulphonylurea (i. e., triple combination therapy) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a sulphonylurea.
Doseringen af antihyperglykæmisk behandling med Velmetia bør individualiseres på basis af patientens aktuelle regime, effektivitet og tolerabilitet, uden at den maksimale anbefalede daglige dosis på 100 mg sitagliptin overskrides.
The dose of antihyperglycaemic therapy with Velmetia should be individualised on the basis of the patient ’ s current regimen, effectiveness, and tolerability while not exceeding the maximum recommended daily dose of 100 mg sitagliptin.
Til patienter, der ikke er tilstrækkeligt kontrolleret på maksimal tolereret dosis af metformin - monoterapi Til patienter, der ikke er tilstrækkeligt kontrolleret på metformin alene, bør den normale startdosis for Velmetia doseres som 50 mg sitagliptin to gange dagligt (100 mg i alt pr. dag) plus den dosis metformin, som allerede tages.
For patients inadequately controlled on maximal tolerated dose of metformin monotherapy For patients not adequately controlled on metformin alone, the usual starting dose of Velmetia should provide sitagliptin dosed as 50 mg twice daily (100 mg total daily dose) plus the dose of metformin already being taken.
Til patienter, der ikke er tilstrækkeligt kontrolleret på dual kombinationsbehandling med den maksimale tolererede dosis af metformin og et sulfonylurinstof Velmetia bør doseres som sitagliptin 50 mg to gange dagligt (100 mg i alt pr. dag), og metformin bør gives i en dosis svarende til den, som allerede tages.
For patients inadequately controlled on dual combination therapy with the maximal tolerated dose of metformin and a sulphonylurea The dose of Velmetia should provide sitagliptin dosed as 50 mg twice daily (100 mg total daily dose) and a dose of metformin similar to the dose already being taken.
4. 4).
When Velmetia is used in combination with a sulphonylurea, a lower dose of the sulphonylurea may be required to reduce the risk of hypoglycaemia (see section 4.4).
2 Til de forskellige metformindoser findes Velmetia i styrker på 50 mg sitagliptin og 850 mg metforminhydrochlorid eller 1. 000 mg metforminhydrochlorid.
2 For the different doses on metformin, Velmetia is available in strengths of 50 mg sitagliptin and 850 mg metformin hydrochloride or 1000 mg metformin hydrochloride.
Velmetia bør gives to gange dagligt sammen med et måltid for at reducere de gastrointestinale bivirkninger, der er forbundet med metformin.
Velmetia should be given twice daily with meals to reduce the gastrointestinal undesirable effects associated with metformin.
4. 3 og 4. 4).
Patients with renal insufficiency Velmetia should not be used in patients with moderate or severe renal impairment (creatinine clearance < 60 ml/ min) (see sections 4.3 and 4.4).
4. 3 og 5. 2).
Patients with hepatic insufficiency Velmetia should not be used in patients with hepatic impairment (see sections 4.3 and 5.2).
Ældre Da metformin og sitagliptin udskilles via nyrerne, bør Velmetia anvendes med forsigtighed efterhånden som alderen stiger.
Elderly As metformin and sitagliptin are excreted by the kidney, Velmetia should be used with caution as age increases.
Børn Velmetia bør ikke anvendes til børn under 18 år p. g. a. manglende dokumentation for sikkerhed og virkning hos denne gruppe.
Paediatric population Velmetia is not recommended for use in children below 18 years of age due to a lack of data on its safety and efficacy in this population.
Generelt Velmetia bør ikke anvendes til patienter med type 1- diabetes og må ikke anvendes til behandling af diabetisk ketoacidose.
General Velmetia should not be used in patients with type 1 diabetes and must not be used for the treatment of diabetic ketoacidosis.
Hypoglykæmi Patienter, der får Velmetia sammen med et sulfonylurinstof, har øget risiko for at få hypoglykæmi.
Hypoglycaemia Patients receiving Velmetia in combination with a sulphonylurea may be at risk for hypoglycaemia.
Anvendelse af Velmetia sammen med insulin er ikke blevet tilstrækkeligt undersøgt.
The use of Velmetia in combination with insulin has not been adequately studied.
4. 8).
If a hypersensitivity reaction is suspected, discontinue Velmetia, assess for other potential causes of the event, and institute alternative treatment for diabetes (see section 4.8).
Operation Da Velmetia indeholder metforminhydrochlorid, bør behandlingen seponeres 48 timer før elektiv operation med generel, spinal eller epidural anæstesi.
Surgery As Velmetia contains metformin hydrochloride, the treatment should be discontinued 48 hours before elective surgery with general, spinal or epidural anaesthesia.
Behandling med Velmetia bør sædvanligvis ikke genoptages tidligere end 48 timer herefter og kun efter, at nyrefunktionen er blevet revurderet og fundet normal.
Velmetia should not usually be resumed earlier than 48 hours afterwards and only after renal function has been re-evaluated and found to be normal.
4. 5).
Therefore, Velmetia should be discontinued prior to, or at the time of the test and not reinstituted until 48 hours afterwards, and only after renal function has been re-evaluated and found to be normal (see section 4.5).
Ændring i klinisk status hos patienter med tidligere velbehandlet type 2- diabetes En patient med type 2- diabetes, der tidligere var velbehandlet på Velmetia, og som udvikler unormale laboratorieværdier eller klinisk sygdom (især vagt eller uklart defineret sygdom) bør vurderes hurtigt med henblik på tegn på ketoacidose eller laktacidose.
4 Change in clinical status of patients with previously controlled type 2 diabetes A patient with type 2 diabetes previously well controlled on Velmetia who develops laboratory abnormalities or clinical illness (especially vague and poorly defined illness) should be evaluated promptly for evidence of ketoacidosis or lactic acidosis.
Hvis acidose i en eller anden form forekommer, skal Velmetia stoppes omgående, og andre hensigtsmæssige og korrigerende handlinger initieres.
If acidosis of either form occurs, Velmetia must be stopped immediately and other appropriate corrective measures initiated.
Der er ikke udført farmakokinetiske interaktionsundersøgelser med Velmetia, men sådanne undersøgelser er udført med de enkelte aktive stoffer i Velmetia, sitagliptin og metformin.
Pharmacokinetic drug interaction studies with Velmetia have not been performed; however, such studies have been conducted with the individual active substances of Velmetia, sitagliptin and metformin.
Der er øget risiko for laktacidose ved akut alkoholforgiftning (især i tilfælde af faste, dårlig ernæringstilstand eller leverinsufficiens) på grund af den aktive metforminsubstans i Velmetia (se pkt.
There is increased risk of lactic acidosis in acute alcohol intoxication (particularly in the case of fasting, malnutrition or hepatic insufficiency) due to the metformin active substance of Velmetia (see section 4.4).
4. 4).
Therefore, Velmetia should be discontinued prior to, or at the time of the test and not reinstituted until 48 hours afterwards, and only after renal function has been re-evaluated and found to be normal (see section 4.4).
Hvis en patient ønsker at blive gravid eller bliver gravid, bør behandling med Velmetia seponeres, og der bør skiftes til insulinbehandling så snart som muligt.
If a patient wishes to become pregnant or if a pregnancy occurs, treatment with Velmetia should be discontinued and switched to insulin treatment as soon as possible.
Der er ikke udført undersøgelser på diegivende dyr med de kombinerede aktive stoffer i Velmetia.
No studies in lactating animals have been conducted with the combined active substances of Velmetia.
4. 3).
Velmetia must therefore not be used in women who are breast-feeding (see section 4.3).
Der er ikke foretaget undersøgelser af virkningen af Velmetia på evnen til at føre motorkøretøj eller betjene maskiner.
No studies on the effects on the ability to drive and use machines have been performed with Velmetia.
Desuden bør patienter advares om risikoen for hypoglykæmi, når Velmetia anvendes sammen med andre sulfonylurinstoffer.
In addition, patients should be alerted to the risk of hypoglycaemia when Velmetia is used in combination with other sulfonylurea agents.
5. 2).
There have been no therapeutic clinical trials conducted with Velmetia tablets however bioequivalence of Velmetia with co-administered sitagliptin and metformin has been demonstrated (see section 5.2).
Til sammenligning var bivirkningsincidensen 7, 1% hos de patienter, der blev behandlet med placebo og glimepirid/ metformin.
7 considered as drug-related in patients treated with the addition of sitagliptin to the ongoing treatment with glimepiride and metformin was 18.1% compared to treatment with the addition of placebo to the ongoing treatment with glimepiride and metformin which was 7.1%.
4. 4).
During post-marketing experience of Velmetia or sitagliptin, one of the active substances of Velmetia, the following additional adverse reactions have been reported (frequency not known): hypersensitivity reactions including anaphylaxis, angioedema, rash, urticaria, and exfoliative skin conditions including Stevens-Johnson syndrome (see section 4.4).
Der findes ingen tilgængelige data vedrørende overdosering af Velmetia.
No data are available with regard to overdose of Velmetia.
Sitagliptinphosphat, en dipeptylpeptidase- 4- hæmmer (DPP- 4), og metforminhydrochlorid, der tilhører biguanidklassen.
Velmetia combines two antihyperglycaemic agents with complementary mechanisms of action to improve glycaemic control in patients with type 2 diabetes: sitagliptin phosphate, a dipeptidyl peptidase 4 (DPP-4) inhibitor, and metformin hydrochloride, a member of the biguanide class.
Sitagliptinphosphat er en oralt aktiv, potent og højselektiv hæmmer af DPP- 4- enzymet til behandling af type 2- diabetes.
9 Sitagliptin Sitagliptin phosphate is an orally-active, potent, and highly selective inhibitor of the dipeptidyl peptidase 4 (DPP-4) enzyme for the treatment of type 2 diabetes.
Sitagliptin adskiller sig i kemisk struktur og farmakologisk virkning fra GLP- 1- analoger, insulin, sulfonylurinstoffer eller meglitinider, biguanider, peroxisom- proliferatoraktiverede receptorgammaagonister (PPARγ), alfaglucosidasehæmmere og amylinanaloger.
Sitagliptin differs in chemical structure and pharmacological action from GLP-1 analogues, insulin, sulphonylureas or meglitinides, biguanides, peroxisome proliferator-activated receptor gamma (PPAR γ) agonists, alpha- glucosidase inhibitors, and amylin analogues.
Patienter, der blev behandlet med sitagliptin havde en moderat vægtøgning (+1, 1 kg) sammenlignet med de patienter, der fik placebo.
Patients treated with sitagliptin had a modest increase in body weight (+1.1 kg) compared to those given placebo.
(%) i 24. uge †
in HbA1c (%) at Week 24 †
i 24. uge †
at Week 24 †
- 0, 7 ‡
-0.7 ‡
Velmetia En bioækvivalensundersøgelse med raske forsøgspersoner viste, at Velmetia (sitagliptin/ metforminhydrochlorid) kombinationstabletter er bioækvivalente med samtidig administration af sitagliptinphosphat og metforminhydrochlorid som individuelle tabletter.
Velmetia A bioequivalence study in healthy subjects demonstrated that the Velmetia (sitagliptin/ metformin hydrochloride) combination tablets are bioequivalent to co-administration of sitagliptin phosphate and metformin hydrochloride as individual tablets.
13 Ældre Dosisjustering er ikke nødvendig på basis af alder.
Elderly No dose adjustment is required based on age.
14 Sitagliptin Der blev observeret nyre - og levertoksicitet hos gnavere ved systemiske eksponeringsniveauer, der var 58 gange højere end eksponeringsniveauet hos mennesker, mens no- effect- niveauet fandtes ved et niveau, der var 19 gange højere end eksponeringsniveauet hos mennesker.
Sitagliptin Renal and liver toxicity were observed in rodents at systemic exposure values 58 times the human exposure level, while the no-effect level was found at 19 times the human exposure level.
EU/ 1/ 08/ 456/ 001 EU/ 1/ 08/ 456/ 002 EU/ 1/ 08/ 456/ 003 EU/ 1/ 08/ 456/ 004 EU/ 1/ 08/ 456/ 005 EU/ 1/ 08/ 456/ 006 EU/ 1/ 08/ 456/ 007 EU/ 1/ 08/ 456/ 015 9.
EU/ 1/ 08/ 456/ 001 EU/ 1/ 08/ 456/ 002 EU/ 1/ 08/ 456/ 003 EU/ 1/ 08/ 456/ 004 EU/ 1/ 08/ 456/ 005 EU/ 1/ 08/ 456/ 006 EU/ 1/ 08/ 456/ 007 EU/ 1/ 08/ 456/ 015
16 10.
16 1.
Velmetia 50 mg/ 1000 mg filmovertrukne tabletter.
Velmetia 50 mg/ 1000 mg film-coated tablets
Kapselformet, rød filmovertrukken tablet med "577" præget på den ene side.
Capsule-shaped, red film-coated tablet with “ 577 ” debossed on one side.
Doseringen af antihyperglykæmisk behandling med Velmetia bør individualiseres på basis af patientens aktuelle regime, effektivitet og tolerabilitet, uden at denne må overstige den maksimale anbefalede daglige dosis på 100 mg sitagliptin overskrides.
The dose of antihyperglycaemic therapy with Velmetia should be individualised on the basis of the patient ’ s current regimen, effectiveness, and tolerability while not exceeding the maximum recommended daily dose of 100 mg sitagliptin.
18 Til de forskellige metformindoser findes Velmetia i styrker på 50 mg sitagliptin og 850 mg metforminhydrochlorid eller 1. 000 mg metforminhydrochlorid.
17 For the different doses on metformin, Velmetia is available in strengths of 50 mg sitagliptin and 850 mg metformin hydrochloride or 1,000 mg metformin hydrochloride.
Ændring i klinisk status hos patienter med tidligere velbehandlet type 2- diabetes En patient med type 2- diabetes, der tidligere var velbehandlet på Velmetia, og som udvikler unormale laboratorieværdier eller klinisk sygdom (især vagt eller uklart defineret sygdom) bør vurderes hurtigt med henblik på tegn på ketoacidose eller laktacidose.
19 Change in clinical status of patients with previously controlled type 2 diabetes A patient with type 2 diabetes previously well controlled on Velmetia who develops laboratory abnormalities or clinical illness (especially vague and poorly defined illness) should be evaluated promptly for evidence of ketoacidosis or lactic acidosis.
Til sammenligning var bivirkningsincidensen 7, 1% hos de patienter, der blev behandlet med placebo og glimepirid/ metformin.
22 considered as drug-related in patients treated with the addition of sitagliptin to the ongoing treatment with glimepiride and metformin was 18.1% compared to treatment with the addition of placebo to the ongoing treatment with glimepiride and metformin which was 7.1%.
Velmetia er en kombination af to antihyperglykæmiske præparater med komplementære virkningsmekanismer til forbedring af glykæmisk kontrol hos patienter med type 2- diabetes: sitagliptinphosphat, en dipeptylpeptidase- 4- hæmmer (DPP- 4), og metforminhydrochlorid, der tilhører biguanidklassen.
24 Velmetia combines two antihyperglycaemic agents with complementary mechanisms of action to improve glycaemic control in patients with type 2 diabetes: sitagliptin phosphate, a dipeptidyl peptidase 4 (DPP-4) inhibitor, and metformin hydrochloride, a member of the biguanide class.
EU/ 1/ 08/ 456/ 008 EU/ 1/ 08/ 456/ 009 EU/ 1/ 08/ 456/ 010 EU/ 1/ 08/ 456/ 011 EU/ 1/ 08/ 456/ 012 EU/ 1/ 08/ 456/ 013 EU/ 1/ 08/ 456/ 014 EU/ 1/ 08/ 456/ 016
EU/ 1/ 08/ 456/ 008 EU/ 1/ 08/ 456/ 009 EU/ 1/ 08/ 456/ 010 EU/ 1/ 08/ 456/ 011 EU/ 1/ 08/ 456/ 012 EU/ 1/ 08/ 456/ 013 EU/ 1/ 08/ 456/ 014 EU/ 1/ 08/ 456/ 016
Ydre karton til VELMETIA 50 mg/ 850 mg filmovertrukne tabletter
Outer carton for Velmetia 50 mg/ 850 mg film-coated tablets
Velmetia 50 mg/ 850 mg filmovertrukne tabletter Sitagliptin/ metforminhydrochlorid
Velmetia 50 mg/ 850 mg film-coated tablets sitagliptin/ metformin hydrochloride
EU/ 1/ 08/ 456/ 00114 filmovertrukne tabletter EU/ 1/ 08/ 456/ 002 28 filmovertrukne tabletter EU/ 1/ 08/ 456/ 003 56 filmovertrukne tabletter EU/ 1/ 08/ 456/ 004 112 filmovertrukne tabletter EU/ 1/ 08/ 456/ 005 168 filmovertrukne tabletter EU/ 1/ 08/ 456/ 006 196 filmovertrukne tabletter EU/ 1/ 08/ 456/ 007 50 x 1 filmovertrukne tabletter EU/ 1/ 08/ 456/ 015 196 (2 x 98) filmovertrukne tabletter
EU/ 1/ 08/ 456/ 001 14 film-coated tablets EU/ 1/ 08/ 456/ 002 28 film-coated tablets EU/ 1/ 08/ 456/ 003 56 film-coated tablets EU/ 1/ 08/ 456/ 004 112 film-coated tablets EU/ 1/ 08/ 456/ 005 168 film-coated tablets EU/ 1/ 08/ 456/ 006 196 film-coated tablets EU/ 1/ 08/ 456/ 007 50 x 1 film-coated tablets EU/ 1/ 08/ 456/ 015 196 (2 x 98) film-coated tablets
Multipakning med 196 (2 pakninger med 98 filmovertrukne tabletter) – uden Blue Box 50 mg/ 1. 000 mg filmovertrukne tabletter
Multi-packs of 196 (2 packs of 98 film-coated tablets) – without blue box - 50 mg/ 850 mg film- coated tablets
Velmetia 50 mg/ 850 mg filmovertrukne tabletter sitagliptin/ metforminhydrochlorid
Velmetia 50 mg/ 850 mg film-coated tablets sitagliptin/ metformin hydrochloride
MINDSTEKRAV TIL MÆRKNING PÅ BLISTERKORT
39 MINIMUM PARTICULARS TO APPEAR ON BLISTERS
Blister til VELMETIA 50 mg/ 850 mg filmovertrukne tabletter
Blister for Velmetia 50 mg/ 850 mg film-coated tablets
Velmetia 50 mg/ 850 mg tabletter sitagliptin/ metforminhydrochlorid
Velmetia 50 mg/ 850 mg tablets sitagliptin/ metformin HCl
Ydre karton til VELMETIA 50 mg/ 1. 000 mg filmovertrukne tabletter
Outer carton for Velmetia 50 mg/ 1,000 mg film-coated tablets
Velmetia 50 mg/ 1. 000 mg filmovertrukne tabletter Sitagliptin/ metforminhydrochlorid
Velmetia 50 mg/ 1,000 mg film-coated tablets sitagliptin/ metformin hydrochloride
EU/ 1/ 08/ 456/ 008 14 filmovertrukne tabletter EU/ 1/ 08/ 456/ 009 28 filmovertrukne tabletter EU/ 1/ 08/ 456/ 010 56 filmovertrukne tabletter EU/ 1/ 08/ 456/ 011 112 filmovertrukne tabletter EU/ 1/ 08/ 456/ 012 168 filmovertrukne tabletter EU/ 1/ 08/ 456/ 013 196 filmovertrukne tabletter EU/ 1/ 08/ 456/ 01450 x 1 filmovertrukne tabletter EU/ 1/ 08/ 456/ 016 196 (2 x 98) filmovertrukne tabletter
EU/ 1/ 08/ 456/ 008 14 film-coated tablets EU/ 1/ 08/ 456/ 009 28 film-coated tablets EU/ 1/ 08/ 456/ 010 56 film-coated tablets EU/ 1/ 08/ 456/ 011 112 film-coated tablets EU/ 1/ 08/ 456/ 012 168 film-coated tablets EU/ 1/ 08/ 456/ 013 196 film-coated tablets EU/ 1/ 08/ 456/ 014 50 x 1 film-coated tablets EU/ 1/ 08/ 456/ 016196 (2 x 98) film-coated tablets
Velmetia 50 mg 1. 000 mg
Velmetia 50 mg 1,000 mg
Velmetia 50 mg/ 850 mg filmovertrukne tabletter sitagliptin/ metforminhydrochlorid
Velmetia 50 mg/ 1,000 mg film-coated tablets sitagliptin/ metformin hydrochloride
Hver tablet indeholder 50 mg sitagliptin (som phosphatmonohydrat) og 850 mg metforminhydrochlorid.
Each tablet contains 50 mg of sitagliptin (as phosphate monohydrate) and 1,000 mg of metformin hydrochloride.
Blister til VELMETIA 50 mg/ 1000 mg filmovertrukne tabletter
Blister for Velmetia 50 mg/ 1,000 mg film-coated tablets
Velmetia 50 mg/ 1000 mg tabletter sitagliptin/ metforminhydrochlorid
Velmetia 50 mg/ 1,000 mg tablets sitagliptin/ metformin HCl
Velmetia 50 mg/ 850 mg filmovertrukne tabletter (sitagliptin/ metforminhydrochlorid)
Velmetia 50 mg/ 850 mg film-coated tablets sitagliptin/ metformin hydrochloride
- Lægen har ordineret Velmetia til Dem personligt.
- This medicine has been prescribed for you.
Velmetias virkning og hvad De skal bruge det til 2.
What Velmetia is and what it is used for 2.
Det skal De vide, før De begynder at tage Velmetia 3.
Before you take Velmetia 3.
Sådan skal De tage Velmetia 4.
How to take Velmetia 4.
Sådan opbevarer De Velmetia 6.
How to store Velmetia 6.
VELMETIAS VIRKNING OG HVAD DE SKAL BRUGE DET TIL
WHAT VELMETIA IS AND WHAT IT IS USED FOR
Navnet på tabletten er Velmetia.
The name of your tablet is Velmetia.
Velmetia hjælper med at forbedre insulinniveauet efter et måltid og nedsætter mængden af sukker, der dannes af kroppen.
Velmetia helps to improve the levels of insulin after a meal and lowers the amount of sugar made by your body.
Velmetia kan bruges alene eller sammen med en anden medicin, som kaldes et sulfonylurinstof, til behandling af diabetes.
Velmetia can be used alone or with another medicine for diabetes called a sulphonylurea.
DET SKAL DE VIDE, FØR DE BEGYNDER AT TAGE VELMETIA
BEFORE YOU TAKE VELMETIA
Tag ikke Velmetia:
Do not take Velmetia:
indholdsstoffer i Velmetia.
Velmetia (listed in section 6)
nødvendigt at stoppe med Velmetia på tidspunktet for røntgenundersøgelsen og et par dage efter.
taking Velmetia at the time of the X-ray and for a few days after
Tag ikke Velmetia, hvis De mener noget af dette passer på Dem.
Do not take Velmetia if any of the above apply to you.
Er De i tvivl, så spørg lægen eller apoteket, før De tager Velmetia.
If you are not sure, talk to your doctor or pharmacist before taking Velmetia.
Vær ekstra forsigtig med at tage Velmetia Spørg lægen eller på apoteket, før De tager Deres medicin:
Take special care with Velmetia Check with your doctor or pharmacist before taking your medicine:
Hvis De oplever symptomer på laktacidose, skal De stoppe med at tage Velmetia og straks kontakte en læge.
If you experience some of the symptoms of lactic acidosis stop taking Velmetia and consult a doctor immediately
- Under behandlingen med Velmetia vil lægen kontrollere Deres nyrefunktion mindst én gang om
- During treatment with Velmetia, your doctor will check your kidney function at least once a
året og oftere, hvis De er ældre, eller Deres nyrefunktion er på grænsen til det normale eller i risiko for at blive værre.
year and more frequently if you are elderly or if your kidney function is borderline or at risk of worsening
- Hvis De har eller har haft en allergisk reaktion over for sitagliptin, metformin eller Velmetia.
- if you have or have had an allergic reaction to sitagliptin, metformin, or Velmetia
- Hvis De tager anden diabetesmedicin, kaldet et sulfonylurinstof, sammen med Velmetia, da De
- if you are taking a sulphonylurea, a diabetes medicine, together with Velmetia, as you may
- Hvis De skal opereres under fuld bedøvelse, underrygmarvsbedøvelse eller epiruralblokade, da
You may
det så kan være nødvendigt at stoppe med at tage Velmetia i et par dage før og efter operationen.
need to stop taking Velmetia for a couple of days before and after the procedure
Hvis De er i tvivl om noget af ovenstående passer på Dem, skal De tale med lægen eller apoteket, før De tager Velmetia.
If you are not sure if any of the above apply to you, talk to your doctor or pharmacist before taking Velmetia.